Estrogen Receptor, Progesterone Receptor Breast Cancer Testing

Also Known As

Estrogen Receptors

Progesterone Receptors

ER and PR Status

Hormone Receptor Status

Formal Name

Estrogen and Progesterone Receptor Status

This article was last reviewed on

January 16, 2019.

This article waslast modified on January 27, 2021.

At a Glance

Why Get Tested?

Hormone receptor tests determine if an invasive breast cancer is positive for estrogen and progesterone receptors, helping to guide treatment.

When To Get Tested?

When you have been diagnosed with invasive breast cancer or when your cancer has recurred or metastasized;
When hormone receptor test results were initially negative on a biopsy, and a subsequent specimen becomes available, repeat testing may be considered.

Sample Required?

A sample of breast cancer cells or tissue obtained by doing a fine needle aspiration, needle biopsy, or surgical biopsy, or when a tumor is removed surgically during a lumpectomy or mastectomy

Test Preparation Needed?

The healthcare practitioner who will obtain the sample for testing will provide instructions for how to prepare for the procedure.

You may be able to find your test results on your laboratory's website or patient portal. However, you are currently at Lab Tests Online. You may have been directed here by your lab's website in order to provide you with background information about the test(s) you had performed. You will need to return to your lab's website or portal, or contact your healthcare practitioner in order to obtain your test results.

Lab Tests Online is an award-winning patient education website offering information on laboratory tests. The content on the site, which has been reviewed by laboratory scientists and other medical professionals, provides general explanations of what results might mean for each test listed on the site, such as what a high or low value might suggest to your healthcare practitioner about your health or medical condition.

The reference ranges for your tests can be found on your laboratory report. They are typically found to the right of your results.

If you do not have your lab report, consult your healthcare provider or the laboratory that performed the test(s) to obtain the reference range.

Laboratory test results are not meaningful by themselves. Their meaning comes from comparison to reference ranges. Reference ranges are the values expected for a healthy person. They are sometimes called "normal" values. By comparing your test results with reference values, you and your healthcare provider can see if any of your test results fall outside the range of expected values. Values that are outside expected ranges can provide clues to help identify possible conditions or diseases.

While accuracy of laboratory testing has significantly evolved over the past few decades, some lab-to-lab variability can occur due to differences in testing equipment, chemical reagents, and techniques. This is a reason why so few reference ranges are provided on this site. It is important to know that you must use the range supplied by the laboratory that performed your test to evaluate whether your results are "within normal limits."

For more information, please read the article Reference Ranges and What They Mean.

What is being tested?

Receptors are specialized proteins on the surface of or within cells that bind to specific substances. The binding typically has a specific effect on the cells. Many, but not all, breast cancer cells have receptors that bind to the hormones estrogen and/or progesterone. Breast cancer tumors with estrogen receptors (ER) and/or progesterone receptors (PR) typically depend on the hormones to grow and divide. ER and PR testing of breast tumor tissue determines if one or both types of receptors are present. About two out of three breast cancers are positive for ER and PR.

Common Questions

How is the test used?

Hormone receptor testing of breast tumor tissue is used to determine if estrogen receptors (ER) and/or progesterone receptors (PR) are present and whether the tumor tissues depend on estrogen and/or progesterone to grow. Knowing if a tumor grows under the influence of hormones indicates whether removal of one's ovaries, which produce the hormones, or blocking the hormones with drugs (hormone therapy or endocrine therapy) can inhibit tumor growth to prolong survival. Studies have demonstrated a benefit from such hormone therapy for patients with ER-positive tumors.
When is it ordered?

In 2010, the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) jointly published guidelines that recommend that all tumors from individuals with newly diagnosed invasive breast cancer be evaluated for estrogen and progesterone receptors. The guidelines also state that all recurrent breast cancers should be tested and that the option of testing should be provided for patients who have non-invasive breast cancer.

A 2015 ASCO Clinical Practice Guideline reaffirmed that retesting of metastatic tumors for ER and PR receptors should be offered, although it is unclear whether changing treatment on the basis of a change in receptor test results affects clinical outcomes.

The 2017 NCCN guideline for breast cancer also recommends ER testing for ER and PR for invasive breast cancer.
What does the test result mean?
The results for ER receptor and PR receptor testing cover a range from low to high levels of receptor expression. Patients receive greater benefit from hormone therapy if their breast tumor has more ER receptors. Studies indicate that tumors with less receptor expression are less likely to respond to the therapies that aim to reduce stimulation of the receptors such as tamoxifen, but even low positivity may be associated with some response. The more receptors present, the more likely the response.

Guidelines recommend classifying tumors with as few as 1% positive cells as receptor positive, but for tumors with low ER expression, the decision for targeted therapy should be based on an analysis of its risks versus potential benefits. If a person's cancer is ER-negative but PR-positive, or ER-positive but PR-negative, then the person may still benefit from hormone therapy.

If the cancer is both ER-negative and PR-negative, then the person is not likely to benefit from hormone therapy.

An individual's response to hormone therapy will depend on a variety of factors, but typical approximate response rates include:

ER-positive, PR-positive: 75-80%

ER-positive, PR-negative: 40-50%

ER-negative, PR-positive: 25-30%

ER-negative, PR-negative: 10% or less

If there is a discrepancy between test results after testing a primary and a metastatic tumor sample, many times the ER and PR status of the metastasis can be used to guide therapy when considered in the context of the clinical scenario and your treatment goals.
What other testing might be done?

HER2 testing is typically done at the same time as hormone receptor status testing. Additional treatment options are possible for tumors that are HER2-positive and these cancers may benefit from anti-HER2 therapy regardless of hormone receptor status. Also, a healthcare practitioner may decide on a case-by-case basis whether to offer breast cancer gene expression profiling and, based on the results (as well as other factors), whether to offer additional treatment.
I was diagnosed with ductal-carcinoma in situ. Will hormone receptor testing be done?

When you have been diagnosed with ductal-carcinoma in situ (DCIS, cancer confined to the breast ducts), you and your physician may choose to determine estrogen receptor status depending upon your treatment preferences. The 2017 NCCN guideline for breast cancer recommends ER testing DCIS. Results of ER testing of DCIS can help determine whether there may be an opportunity for adjuvant hormone therapy and reducing risk for recurrence or progression to invasive breast cancer.
How long will it take for results?

Hormone receptor status testing is not available in every laboratory. It requires experience and special training to perform and interpret. A healthcare practitioner will often send a sample to a reference laboratory and it may take several days to weeks before the results are available. It is recommended that testing be done by a lab that follows the American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations to avoid inaccurate results.
Can a blood sample be used instead of a tissue sample to perform these tests?

At present, there isn't a blood test that can substitute for testing tumor tissue obtained from a biopsy or surgically.
Would this testing also be performed on a man?

Yes. Men do not get breast cancer as frequently as women, but it does occur and their cancer may also be ER- or PR-positive.
Is there anything else I should know?

It takes a small amount of cancer tissue to perform hormone receptor status testing. If a sufficient sample is not available, your healthcare practitioner may make an assumption that your cancer is ER-positive and PR-positive in order to broaden the treatment options. However, for women with ER-negative invasive breast cancer, studies have demonstrated no benefit from endocrine treatments.

While uncommon, truly ER-negative but PR-positive invasive breast tumors are also considered eligible for hormone therapy. Receptor status may provide some information about prognosis.

You may obtain a copy of your ER and PR test report and review the results with your healthcare practitioner to fully understand the results.

See More Common Questions See Less Common Questions

Ask a Laboratory Scientist

This form enables patients to ask specific questions about lab tests. Your questions will be answered by a laboratory scientist as part of a voluntary service provided by one of our partners, American Society for Clinical Laboratory Science. Please allow 2-3 business days for an email response from one of the volunteers on the Consumer Information Response Team.

Please indicate whether you are a

Country

I have read and agree to the Privacy Policy (read the Privacy Policy)

I have read and agree to the Terms of Use (read the Terms of Use)

I agree to the disclaimer (read the disclaimer).

Disclaimer

Thank you for using the Consumer Information Response Service (“the Service”) to inquire about the meaning of your lab test result. The Service is provided free of charge by the American Society for Clinical Laboratory Science.

Please note that information provided through this free Service is not intended to be medical advice and should not be relied on as such. Although the laboratory strives to provide the largest single source of objective, scientific data on patient status, it is only one part of a complex biological picture of health or disease. As professional clinical laboratory scientists, our goal is to assist you in understanding the purpose of laboratory tests and the general meaning of your laboratory results. It is important that you communicate with your physician so that together you can integrate the pertinent information, such as age, ethnicity, health history, signs and symptoms, laboratory and other procedures (radiology, endoscopy, etc.) to determine your health status. The information provided through this Service is not intended to substitute for such consultations with your physician nor specific medical advice to your health condition.

By submitting your question to this Service, you agree to release and hold harmless the American Society for Clinical Laboratory Science and its affiliates or their past or present officers, directors, employees, agents and Service volunteers (collectively referred to as “ASCLS”) and Lab Tests, LLC and its affiliates or their past or present members, managers, officers, directors, employees, agents and Service volunteers (collectively referred to as the “LT Parties”) from any legal claims, rights or causes of action you may have relating to or arising out of your use of the Service or in connection with the responses provided to the questions that you submit to the Service.

ASCLS and the LT Parties hereby disclaim any and all liability arising out of your use of this Service or for any adverse outcome from your use of the information provided by this Service for any reason, including but not limited to any misunderstanding or misinterpretation of the information provided through this Service.

See Full Form See Less

Estrogen Receptor, Progesterone Receptor Breast Cancer Testing

On This Site

Elsewhere On The Web

Ask a Laboratory Scientist